This ensures that the control system can react quickly to the individual phases by actuating values quickly and precisely, ...
The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...
Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.
As the joke goes, CRQC has been 10 to 20 years away for the past three decades. While the recent research suggests that ...
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif. Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration ...
Priority Dispatch Corp., a provider of emergency dispatch protocol systems, has launched a SMART on FHIR application that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results